LifeMD announces launch of Wegovy subscription program

LifeMD (LFMD) announced the launch of Novo Nordisk’s (NVO) new Wegovy subscription program is now available through LifeMD. “The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings. The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable formulations and $600 for oral therapy,” LifeMD said in a statement. LifeMD shares are up 6% to $3.81 in premarket trading.